Please wait while the transcript is being prepared...
Interviewer: Dr. Scot Roberts,
welcome and thank you for
taking the time to do this interview with
us today to discuss Altimmune's efforts
in developing a SARS-CoV-2 vaccine.
Let me start by asking you about previous
efforts already deployed to create novel
Altimmune is currently testing at least
two vaccines in clinical trials, one for
the 'flu and another for anthrax.
What is the general mechanism by which
recombinant adenoviral vaccines induce
Dr. Roberts: Let me start by saying
it's a pleasure to be here today.
The approach to create our vaccines
makes use of a viral vector to deliver
the antigen to the host (the patient) so
that it can develop an immune response.
That approach is really quite different
from the vaccines that most of
us are familiar with and
that we've grown up with.
Those vaccines are typically administered
as a shot into the muscle and
what they're doing is presenting
proteins to the immune system,
usually the pathogen that you're
trying to make a vaccine against,
the virus or bacterium in a killed form.
They present those proteins
outside of cells to
the immune system primarily B-cells and
antigen-presenting cells, and
those cells see the proteins and
then can initiate an immune response that
can allow you to respond more quickly
if you encounter that pathogen again.
That's the old technology, but
our approach is to use a live viral vector
that's been disabled, so that it can
no longer replicate once it infects
the cells inside your nose,
because we use intranasal administration.
The advantage of using that
approach is that the virus,